Search results for "antihypertensive agents"

showing 10 items of 184 documents

Improving Knowledge of Arterial Resistant Hypertension: What Is Relevant?

2013

Resistant hypertension, also known as refractory hypertension in the literature, is a relatively common disease that is associated with elevated cardiovascular and renal risk. Clinical trials suggest that its prevalence is around 35% in hypertensive patients with a baseline blood pressure (BP) > 160/100 mmHg. However, data obtained from registries or from the physician’s office suggest that its prevalence is around 12%. The recent National Health and Nutrition Examination Survey suggests a similar prevalence of 12.3% in diagnosed and treated hypertensive patients. An incidence study conducted at Kaiser Permanente Colorado and Kaiser Permanente Northern California followed up more than 200 0…

Malemedicine.medical_specialtyNational Health and Nutrition Examination Surveybusiness.industrymedicine.medical_treatmentDrug ResistanceResistant hypertensionGeneral MedicineClinical trialBlood pressureRefractoryInternal medicineHypertensionEpidemiologymedicineHumansFemaleDiureticbusinessAntihypertensive AgentsMedical literatureRevista Española de Cardiología (English Edition)
researchProduct

Endothelin-1-induced potentiation of adrenergic responses in the rabbit pulmonary artery: role of thromboxane A(2).

2001

Abstract To examine whether low concentrations of endothelin-1 potentiate the vasocontrictor response to adrenergic stimulation, we recorded the isometric response of rings of rabbit pulmonary artery to electrical stimulation and noradrenaline. Endothelin-1 (10 −10 M) potentiated the contractions induced by electrical stimulation and noradrenaline. The endothelin ET B receptor antagonist (2,6-dimethylpiperidinecarbonyl-γ-methyl-Leu- N in -[Methoxycarbonyl]- d -Trp- d -Nle) (BQ-788, 10 −6 M), but not the endothelin ET A receptor antagonist cyclo( d -Asp-Pro- d -Val-Leu- d -TRP) (BQ-123, 10 −6 M), inhibited the potentiating effects of endothelin-1. Pretreatment with the cyclooxygenase inhibit…

Malemedicine.medical_specialtyNifedipineThromboxanemedicine.drug_classAdrenergicPulmonary ArteryThromboxane A2chemistry.chemical_compoundNorepinephrineThromboxane A2PiperidinesInternal medicinemedicineAnimalsVasoconstrictor AgentsAntihypertensive AgentsPharmacologybiologyDose-Response Relationship DrugEndothelin-1Receptors EndothelinReceptor antagonistCalcium Channel BlockersEndothelin 1Receptor Endothelin BElectric StimulationEndocrinologychemistryVasoconstrictionbiology.proteinCyclooxygenaseThromboxane-A synthaseRabbitsEndothelin receptorOligopeptidesEuropean journal of pharmacology
researchProduct

Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension.

2019

Purpose: To evaluate the additive intraocular pressure–lowering effect of twice-daily brinzolamide 1%/brimonidine 0.2% fixed-dose combination (BBFC) as an adjunct to a prostaglandin analog (PGA) in patients with open-angle glaucoma or ocular hypertension insufficiently controlled with PGA monotherapy. Methods: In this Phase 4, double-masked trial, patients aged ⩾18 years, with a mean intraocular pressure of ⩾19 and <32 mm Hg in at least one eye were randomized (1:1) to receive BBFC + PGA ( n = 96) or vehicle + PGA ( n = 92) for 6 weeks. The primary endpoint was the mean change in diurnal intraocular pressure from baseline (averaged over 09:00 and 11:00 h) at Week 6. Results: The mean diu…

Malemedicine.medical_specialtyOpen angle glaucomagenetic structuresFixed-dose combinationBrinzolamideThiazinesOcular hypertensionopen-angle glaucoma03 medical and health sciencesTonometry Ocular0302 clinical medicineTravoprostDouble-Blind Methodintraocular pressure reductionOphthalmologyOriginal Research ArticlesmedicineAdrenergic alpha-2 Receptor AgonistsHumansCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureAgedAged 80 and overSulfonamidesbusiness.industryprostaglandin analogsBrimonidineBrinzolamide/brimonidine fixed-dose combinationGeneral MedicineMiddle Agedmedicine.diseaseAdjuncteye diseasesOphthalmologyDrug CombinationsProstaglandin analogBrimonidine Tartrate030221 ophthalmology & optometryLatanoprostocular hypertensionFemalesense organsbusiness030217 neurology & neurosurgeryGlaucoma Open-Anglemedicine.drugEuropean journal of ophthalmology
researchProduct

Clinical Inertia in Poorly Controlled Elderly Hypertensive Patients: A Cross-Sectional Study in Spanish Physicians to Ascertain Reasons for Not Inten…

2013

Clinical inertia, the failure of physicians to initiate or intensify therapy when indicated, is a major problem in the management of hypertension and may be more prevalent in elderly patients. Overcoming clinical inertia requires understanding its causes and evaluating certain factors, particularly those related to physicians.The objective of our study was to determine the rate of clinical inertia and the physician-reported reasons for it.An observational, cross-sectional, multi-center study was carried out in a primary care setting. We included 512 physicians, with a consecutive sampling of 1,499 hypertensive patients with clinical inertia.Clinical inertia was defined when physicians did n…

Malemedicine.medical_specialtyPediatricsMedicinaCross-sectional studyTreatment outcomeAlternative medicineMEDLINEPharmacotherapyPhysiciansmedicineHumansCorPharmacology (medical)Hypertension diagnosisIntensive care medicineAntihypertensive AgentsAgedPhysician-Patient Relationsbusiness.industryGeneral MedicineMiddle AgedCross-Sectional StudiesTreatment OutcomeMulticenter studySpainHypertensionFemaleClinical CompetenceClinical competenceCardiology and Cardiovascular MedicinebusinessAmerican Journal of Cardiovascular Drugs
researchProduct

Dietary (n-3) polyunsaturated fatty acids exert antihypertensive effects by modulating calcium signaling in T cells of rats.

2001

After 10 wk of feeding an experimental diet enriched with (n-3) polyunsaturated fatty acids (PUFA), i.e., eicosapentaenoic acid [EPA, 20:5(n-3)] and [DHA, 22:6(n-3)] (EPAX), blood pressure in spontaneously hypertensive rats (SHR), but not in normotensive Wistar-Kyoto (WKY) rats was reduced relative to rats fed an unsupplemented control diet. Concanavalin A-stimulated T-cell proliferation was diminished in both strains of rats fed the PUFA/EPAX diet. The experimental diet lowered secretion of interleukin-2 in SHR, but not in WKY rats compared with rats fed the control diet. To determine whether there was a defect in calcium homeostasis in T cells during hypertension, we employed the followin…

Malemedicine.medical_specialtyThapsigarginT-LymphocytesMedicine (miscellaneous)chemistry.chemical_elementCalciumBiologyBinding CompetitiveRats Inbred WKYchemistry.chemical_compoundAldesleukinInternal medicineFatty Acids Omega-6Rats Inbred SHRFatty Acids Omega-3medicineAnimalsCalcium SignalingUnsaturated fatty acidAntihypertensive AgentsPhospholipidsCalcium metabolismchemistry.chemical_classificationImmunosuppression TherapyNutrition and DieteticsVoltage-dependent calcium channelIntracellular MembranesEicosapentaenoic acidDietary FatsRatsEndocrinologychemistryFatty Acids Unsaturatedlipids (amino acids peptides and proteins)Polyunsaturated fatty acidThe Journal of nutrition
researchProduct

Metabolic and Cardiovascular Effects of Switching Thiazides to Amlodipine in Hypertensive Patients With and Without Type 2 Diabetes (the Diuretics an…

2020

Background: Different studies have indicated that thiazide diuretics can increase the risk of developing type 2 diabetes (T2D). Therefore, in this study, we investigated whether switching from hydrochlorothiazide (HCTZ) to amlodipine resulted in ameliorating different cardiovascular and metabolic measures in hypertensive patients with or without T2D. Methods: This study [Diuretics and Diabetes Control (DiaDiC)] was a 6-week, single-blind, single-center randomized controlled trial. The first 20 normal glucose-tolerant, 20 prediabetic, and 20 T2D consecutive patients were randomized to continue the previous antihypertensive treatment with HCTZ (12.5-25 mg/day) or to switch from HCTZ to amlodi…

Malemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismSodium Chloride Symporter InhibitorsdiureticBlood PressureType 2 diabetesSettore MED/13 - EndocrinologiaInternal medicineInternal MedicineMedicineHumansSingle-Blind MethodAmlodipineSettore MED/49 - Scienze Tecniche Dietetiche ApplicateThiazideAntihypertensive AgentsAgedtreatmentbusiness.industryDrug Substitutioncardiovascularfood and beveragesMiddle Agedmedicine.diseaseCalcium Channel BlockersDiabetes controlHydrochlorothiazideTreatment OutcomeDiabetes Mellitus Type 2ItalyHypertensionCardiologyFemaletype 2 diabetesAmlodipinethiazidebusinessEnergy MetabolismmetabolismBiomarkersmedicine.drugMetabolic syndrome and related disorders
researchProduct

Differences in blood pressure control and stroke mortality across Spain: the Prevención de Riesgo de Ictus (PREV-ICTUS) study.

2007

The objective was to assess the stroke risk and prevalence of the cardiovascular risk factors and to analyze their relationship with the specific stroke rates of mortality in each of the autonomic communities of Spain. We conducted a multicenter, cross-sectional study of population >60 years old in Spanish primary care centers. In all of the subjects, clinical, biochemical, and electrocardiographic data were obtained, and the 10-year stroke risk was calculated using the Framingham score. Mortality rates of stroke, age and sex adjusted, were obtained for each of the autonomic communities from the Ministry of Health. A total of 7343 subjects (mean age: 71.6 years, 53.4% women, 34.4% obese…

Malemedicine.medical_specialtyTime FactorsPopulationBlood PressureRisk AssessmentRisk FactorsInternal medicineDiabetes mellitusInternal MedicinemedicinePrevalenceHumanscardiovascular diseasesRisk factoreducationStrokeAntihypertensive AgentsAgededucation.field_of_studyFramingham Risk ScoreVascular diseasebusiness.industryMortality ratemedicine.diseaseSurgeryStrokeBlood pressureCross-Sectional StudiesTreatment OutcomeSpainHypertensionFemaleHypertrophy Left VentricularbusinessHypertension (Dallas, Tex. : 1979)
researchProduct

Effects of the flavonoids extracted from Spergularia purpurea Pers. on arterial blood pressure and renal function in normal and hypertensive rats

2001

The antihypertensive and diuretic effects of the flavonoids extracted from Spergularia purpurea Pers. (SP) were studied both in normotensive (NTR) and spontaneously hypertensive conscious rats (SHR). Daily oral administration of the flavonoid mixture (5 mg/kg for 1 week) exhibited a significant decrease in blood pressure with variation coefficient (Delta) of 20 in SHR rats and 11 in NTR rats. The systolic and diastolic blood pressure decreased significantly and respectively with 17 and 24% in SHR, and with 11 and 16% in NTR. The flavonoid mixture enhanced significantly the water excretion in hypertensive (P<0.001) and normal rats (P<0.001). Furthermore, oral administration of flavonoids mix…

Malemedicine.medical_specialtyUrinary systemmedicine.medical_treatmentAdministration OralRenal functionBlood PressureKidneyKidney Function Testslaw.inventionOral administrationlawRats Inbred SHRInternal medicineDrug DiscoveryHeart ratemedicineAnimalsRats WistarDiureticsAntihypertensive AgentsFlavonoidsPharmacologybiologyPlant Extractsbusiness.industryfood and beveragesbiology.organism_classificationRatsBlood pressureEndocrinologyHypertensionDiureticPhytotherapybusinessSpergulariaJournal of Ethnopharmacology
researchProduct

Fine Structural Evaluation of the Iris After Unilateral Treatment With Latanoprost in Patients Undergoing Bilateral Trabeculectomy (The Mainz II Stud…

2003

Objective To investigate by masked electron microscopy whether 6 months of topical latanoprost caused pathological changes in the peripheral iris of patients with glaucoma. Methods Seventeen patients with bilateral primary open-angle glaucoma requiring trabeculectomy were recruited for this study. The iridectomy taken during surgery on the first eye served as a control. The second test eye was treated topically with latanoprost for 6 months before its trabeculectomy. Fourteen patients completed the treatment arm of the study, and 1 of these underwent marked color change. As a result, 31 iridectomy specimens were fixed, coded, and evaluated. Results The specimens were evaluated for evidence …

Malemedicine.medical_specialtygenetic structuresAdministration Topicalmedicine.medical_treatmentEye diseaseIrisGlaucomaTrabeculectomyMelanocyteExfoliation Syndromechemistry.chemical_compoundDouble-Blind MethodOphthalmologymedicineHumansTrabeculectomyIris (anatomy)LatanoprostAntihypertensive AgentsAgedMelaninsbusiness.industryEye dropMiddle Agedmedicine.diseaseeye diseasesOphthalmologymedicine.anatomical_structurechemistryIridectomyProstaglandins F SyntheticLatanoprostMelanocytesFemalesense organsbusinessGlaucoma Open-AngleArchives of Ophthalmology
researchProduct

Effectiveness and Tolerability of Fixed-Dose Combination Enalapril plus Nitrendipine in Hypertensive Patients Results of the 3-Month Observational, P…

2009

Background and objective: Monotherapy with any class of antihypertensive drug effectively controls blood pressure (BP) in only about 50% of patients. Consequently, the majority of patients with hypertension require combined therapy with two or more medications. This study aimed to evaluate the effectiveness (systolic BP [SBP]/diastolic BP [DBP] control) and tolerability of the fixed-dose combination enalapril/nitrendipine 10 mg/20 mg administered as a single daily dose in hypertensive patients. Methods: This was a post-authorization, multicentre, prospective, observational study conducted in primary care with a 3-month follow-up. Patients throughout Spain with uncontrolled hypertension (>= …

Malemedicine.medical_specialtymedicine.drug_classSystolic hypertensionFixed-dose combinationPopulationAngiotensin-Converting Enzyme InhibitorsBlood PressureEssential hypertensionEnalaprilInternal medicinemedicineProduct Surveillance PostmarketingHumansPharmacology (medical)EnalaprilProspective StudieseducationAntihypertensive drugAntihypertensive Agentseducation.field_of_studyDose-Response Relationship DrugPrimary Health Carebusiness.industryNitrendipineGeneral MedicineMiddle Agedmedicine.diseaseCalcium Channel BlockersDrug CombinationsBlood pressureTolerabilityAnesthesiaHypertensionFemalebusinessmedicine.drug
researchProduct